This article was originally published in The Tan Sheet
Executive SummarySourceOne Global Partners files a lawsuit against KGK Synergize following a dispute about intellectual property originally licensed to SourceOne for KGK's Sytrinol heart health supplement. The complaint filed Dec. 29 in U.S. District Court for the Northern District of Illinois, Eastern Division, says SourceOne's Cholesstrinol supplements do not infringe KGK's patent, and alleges that KGK made false and derogatory statements about SourceOne and its products. In a Jan. 7 statement, London, Ontario-based KGK says the lawsuit is SourceOne's "effort to sidetrack our termination of their license and our letter pointedly telling them to cease and desist their infringement." Chicago-based SourceOne launched the Cholesstrinol line in February 2008 (1"The Tan Sheet" March 17, 2008, p. 14)
You may also be interested in...
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.